168 related articles for article (PubMed ID: 34185780)
1. Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis.
Thapa R; Mondal S; Riikonen J; Rantanen J; Näkki S; Nissinen T; Närvänen A; Lehto VP
PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009533. PubMed ID: 34185780
[TBL] [Abstract][Full Text] [Related]
2. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
Garnier T; Mäntylä A; Järvinen T; Lawrence J; Brown M; Croft S
J Antimicrob Chemother; 2007 Oct; 60(4):802-10. PubMed ID: 17715126
[TBL] [Abstract][Full Text] [Related]
3. Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis.
Smith L; Serrano DR; Mauger M; Bolás-Fernández F; Dea-Ayuela MA; Lalatsa A
Mol Pharm; 2018 Jul; 15(7):2570-2583. PubMed ID: 29762040
[TBL] [Abstract][Full Text] [Related]
4. Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis.
Vexenat JA; Croft SL; Furtado Campos JH; Miles MA
Vet Parasitol; 1998 May; 77(1):71-3. PubMed ID: 9652385
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives.
Mäntylä A; Rautio J; Nevalainen T; Vepsälainen J; Juvonen R; Kendrick H; Garnier T; Croft SL; Järvinen T
Bioorg Med Chem; 2004 Jul; 12(13):3497-502. PubMed ID: 15186834
[TBL] [Abstract][Full Text] [Related]
6. Oleanolic acid loaded poly lactic co- glycolic acid- vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasis.
Ghosh S; Kar N; Bera T
Int J Biol Macromol; 2016 Dec; 93(Pt A):961-970. PubMed ID: 27645930
[TBL] [Abstract][Full Text] [Related]
7. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.
Murray HW; Hariprashad J
Antimicrob Agents Chemother; 1996 Mar; 40(3):586-7. PubMed ID: 8851575
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
[TBL] [Abstract][Full Text] [Related]
9. Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin.
Proulx ME; Désormeaux A; Marquis JF; Olivier M; Bergeron MG
Antimicrob Agents Chemother; 2001 Sep; 45(9):2623-7. PubMed ID: 11502539
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis.
Italia JL; Kumar MN; Carter KC
J Biomed Nanotechnol; 2012 Aug; 8(4):695-702. PubMed ID: 22852479
[TBL] [Abstract][Full Text] [Related]
11. Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies.
Costa Lima SA; Resende M; Silvestre R; Tavares J; Ouaissi A; Lin PK; Cordeiro-da-Silva A
Nanomedicine (Lond); 2012 Dec; 7(12):1839-49. PubMed ID: 22812711
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of artemisinin-loaded nanoparticles in experimental visceral leishmaniasis.
Want MY; Islamuddin M; Chouhan G; Ozbak HA; Hemeg HA; Dasgupta AK; Chattopadhyay AP; Afrin F
Colloids Surf B Biointerfaces; 2015 Jun; 130():215-21. PubMed ID: 25936561
[TBL] [Abstract][Full Text] [Related]
13. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
Jain SK; Sahu R; Walker LA; Tekwani BL
J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
[TBL] [Abstract][Full Text] [Related]
14. Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis.
Want MY; Islammudin M; Chouhan G; Ozbak HA; Hemeg HA; Chattopadhyay AP; Afrin F
Int J Nanomedicine; 2017; 12():2189-2204. PubMed ID: 28356736
[TBL] [Abstract][Full Text] [Related]
15. Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis.
Lalatsa A; Statts L; Adriana de Jesus J; Adewusi O; Auxiliadora Dea-Ayuela M; Bolas-Fernandez F; Dalastra Laurenti M; Felipe Domingues Passero L; Serrano DR
Int J Pharm; 2020 Oct; 588():119734. PubMed ID: 32777535
[TBL] [Abstract][Full Text] [Related]
16. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
17. The activity of plumbagin and other electron carriers against Leishmania donovani and Leishmania mexicana amazonensis.
Croft SL; Evans AT; Neal RA
Ann Trop Med Parasitol; 1985 Dec; 79(6):651-3. PubMed ID: 3834847
[No Abstract] [Full Text] [Related]
18. Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis.
Roberts WL; Hariprashad J; Rainey PM; Murray HW
Am J Trop Med Hyg; 1996 Oct; 55(4):444-6. PubMed ID: 8916804
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Potential of Quercetin-Loaded Nanoemulsion against Experimental Visceral Leishmaniasis:
Das SS; Dubey AK; Verma PRP; Singh SK; Singh SK
Mol Pharm; 2022 Sep; 19(9):3367-3384. PubMed ID: 35980291
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
